The CARB-X 2025 funding round has two distinct themes as described below.
Therapeutics for infections caused by Gram-negative pathogens
The scope is restricted to direct-acting small-molecule therapeutics. Strategies requiring potentiator molecules (including, but not limited to, BLIs, efflux inhibitors, membrane permeators) are not within scope. Molecules with properties that will deliver an IV route with an oral stepdown are preferred. In all cases, activity against both susceptible and multidrug-resistant organisms on priority bacterial threat lists is essential.
View Target Product Profiles and minimal entry criteria here.
Diagnostics for typhoid fever for low-resource settings
We seek a diagnostic to support the portfolio to diagnose acute infection of Salmonella enterica serovar Typhi, the causative pathogen in typhoid fever. The primary health care level is the preferred use setting, with ease-of-use, high performance and affordability prioritized.
View Target Product Profiles and minimal entry criteria here.